Gensight Biologics SA
PAR:SIGHT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gensight Biologics SA
Cash from Financing Activities
Gensight Biologics SA
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Cash from Financing Activities
€8.9m
|
CAGR 3-Years
355%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Cash from Financing Activities
-€621k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Cash from Financing Activities
€49m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Cash from Financing Activities
€249m
|
CAGR 3-Years
88%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Cash from Financing Activities
$275.5m
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
1%
|
|
|
Abivax SA
PAR:ABVX
|
Cash from Financing Activities
€28.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Cash from Financing Activities?
Cash from Financing Activities
8.9m
EUR
Based on the financial report for Dec 31, 2025, Gensight Biologics SA's Cash from Financing Activities amounts to 8.9m EUR.
What is Gensight Biologics SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-23%
Over the last year, the Cash from Financing Activities growth was -34%. The average annual Cash from Financing Activities growth rates for Gensight Biologics SA have been 355% over the past three years , -23% over the past five years .
